Joshua Epstein

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. pmc Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS)
    Huixiao Hong
    Division of Bioinformatics, Z tech at FDA s National Center for Toxicological Research, Jefferson, Arkansas 72079, USA
    BMC Bioinformatics 6:S5. 2005
  2. ncbi request reprint Myeloma and bone disease: "the dangerous tango"
    Joshua Epstein
    Myeloma Institute for Research and Therapy, University of Arkansas Medical Sciences College of Medicine, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 4:300-6. 2006
  3. ncbi request reprint Consequences of interactions between the bone marrow stroma and myeloma
    Joshua Epstein
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Hematol J 4:310-4. 2003
  4. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
  5. doi request reprint NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
    Sathisha Upparahalli Venkateshaiah
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Exp Hematol 41:547-557.e2. 2013
  6. pmc Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
    Lijuan Chen
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 115:61-70. 2010
  7. pmc Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:196-207. 2008
  8. pmc Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3122-5. 2008
  9. pmc Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 776, Little Rock, AR 72205, USA
    Haematologica 91:192-9. 2006
  10. pmc Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3115-21. 2008

Research Grants

Collaborators

Detail Information

Publications50

  1. pmc Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS)
    Huixiao Hong
    Division of Bioinformatics, Z tech at FDA s National Center for Toxicological Research, Jefferson, Arkansas 72079, USA
    BMC Bioinformatics 6:S5. 2005
    ..The use of SELDI data for biomarker identification requires application of rigorous procedures to detect and discard low quality spectra prior to data analysis...
  2. ncbi request reprint Myeloma and bone disease: "the dangerous tango"
    Joshua Epstein
    Myeloma Institute for Research and Therapy, University of Arkansas Medical Sciences College of Medicine, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 4:300-6. 2006
    ..New approaches to enhance osteoblast activity while controlling osteoclast activity currently under investigation may prove effective in controlling lytic bone disease and myeloma progression...
  3. ncbi request reprint Consequences of interactions between the bone marrow stroma and myeloma
    Joshua Epstein
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Hematol J 4:310-4. 2003
    ....
  4. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
    ..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients...
  5. doi request reprint NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
    Sathisha Upparahalli Venkateshaiah
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Exp Hematol 41:547-557.e2. 2013
    ..These findings indicate that MM cells and osteoclasts are highly sensitive to NAD(+) depletion and that PBEF1 inhibition represents a novel approach to target cellular metabolism and inhibit PARP-1 and bone disease in MM...
  6. pmc Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
    Lijuan Chen
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 115:61-70. 2010
    ..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib...
  7. pmc Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:196-207. 2008
    ....
  8. pmc Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3122-5. 2008
    ..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382...
  9. pmc Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 776, Little Rock, AR 72205, USA
    Haematologica 91:192-9. 2006
    ..Whereas those studies focused on the critical role of myeloma-induced osteoclastogenesis in disease progression, little is known about the impact of osteoblasts and increased bone formation on MM...
  10. pmc Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3115-21. 2008
    ..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well...
  11. ncbi request reprint Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 136:393-9. 2007
    ..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM...
  12. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    ..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
  13. pmc F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
    Twyla B Bartel
    Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:2068-76. 2009
    ..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy...
  14. ncbi request reprint Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications
    Ronald Walker
    Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 25:1121-8. 2007
    ..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)...
  15. pmc TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 147:347-51. 2009
    ..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent...
  16. pmc The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
    Simona Colla
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 109:4470-7. 2007
    ..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression...
  17. pmc The Arkansas approach to therapy of patients with multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
    Best Pract Res Clin Haematol 20:761-81. 2007
    ....
  18. pmc Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR and
    Blood 121:4753-7. 2013
    ..Thus, treatment, host, and myeloma features could be linked to MDS development after therapy for this malignancy. This trial was registered at www.clinicaltrials.gov: TT3A: NCT00081939, TT3B: NCT00572169...
  19. pmc Prediction of cytogenetic abnormalities with gene expression profiles
    Yiming Zhou
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 119:e148-50. 2012
    ..The model has an accuracy rate up to 0.89. These results provide proof of concept for the hypothesis that gene expression profiling is a superior genomic method for clinical molecular diagnosis and/or prognosis...
  20. doi request reprint Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 113:355-9. 2008
    ..Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma...
  21. ncbi request reprint Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 137:530-6. 2007
    ....
  22. pmc Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
    Christoph J Heuck
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Clin Cancer Res 18:5499-506. 2012
    ....
  23. pmc An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification
    Owen W Stephens
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 119:503-12. 2012
    ....
  24. pmc Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
    Blood 118:3512-24. 2011
    ..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels...
  25. ncbi request reprint Cancer and the microenvironment: myeloma-osteoclast interactions as a model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR 72205, USA
    Cancer Res 64:2016-23. 2004
    ..These results support data obtained from animal models and clinical observations on the essential role of the microenvironment in tumor sustenance and progression...
  26. pmc Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Br J Haematol 148:726-38. 2010
    ....
  27. ncbi request reprint Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
    Yun Ge
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 133:83-92. 2006
    ..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma...
  28. pmc Proteasome inhibitors and bone disease
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Hematol 49:243-8. 2012
    ..This review will discuss the function of PIs in stimulating bone formation and suppression of bone resorption, and the mechanism underlying this process that leads to inhibition bone disease in MM patients...
  29. ncbi request reprint Antimyeloma efficacy of thalidomide in the SCID-hu model
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 100:4162-8. 2002
    ....
  30. doi request reprint Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
    Rakesh Bam
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Hematol 88:463-71. 2013
    ..These data demonstrate BTK and cell-surface CXCR4 association in myeloma cells and that BTK plays a role in myeloma cell homing to bone and myeloma-induced bone disease. Am. J. Hematol. 88:463-471, 2013. © 2013 Wiley Periodicals, Inc...
  31. ncbi request reprint Heparanase promotes the spontaneous metastasis of myeloma cells to bone
    Yang Yang
    Department of Pathology, Myeloma Institute for Research and Therapy, Center for Orthopaedic Research, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 105:1303-9. 2005
    ..These studies describe a novel experimental animal model for examining the spontaneous metastasis of bone-homing tumors and indicate that heparanase is a critical determinant of myeloma dissemination and growth in vivo...
  32. pmc Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Stem Cells 29:263-73. 2011
    ..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis...
  33. pmc Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
    Sarah Waheed
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Haematologica 98:71-8. 2013
    ..Clinicaltrials.gov identifier: NCT00081939)...
  34. ncbi request reprint Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  35. ncbi request reprint A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
    ..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions...
  36. ncbi request reprint Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
    Bart Barlogie
    Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 107:2633-8. 2006
    ..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma...
  37. ncbi request reprint The SCID-hu myeloma model
    Joshua Epstein
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Science, Little Rock, AK, USA
    Methods Mol Med 113:183-90. 2005
    ..This chapter describes in detail all the steps necessary to establish this model and evaluate its success...
  38. ncbi request reprint Beta(2)-microglobulin as a negative growth regulator of myeloma cells
    Rui Min
    Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 118:495-505. 2002
    ....
  39. ncbi request reprint Soluble syndecan-1 promotes growth of myeloma tumors in vivo
    Yang Yang
    Arkansas Cancer Research Center, Department of Pathology, and the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 100:610-7. 2002
    ..Thus, high levels of soluble syndecan-1 present in patients with myeloma may contribute directly to the growth and dissemination of the malignant cells and thus to poor prognosis...
  40. ncbi request reprint Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
    Shmuel Yaccoby
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:278-90. 2002
    ..Breaking this loop may help control myeloma...
  41. ncbi request reprint Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....
  42. ncbi request reprint Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools
    Sudeepa Bhattacharyya
    Department of Orthopaedic Surgery, Center for Orthopaedic Research, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Dis Markers 22:245-55. 2006
    ....
  43. pmc High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
    Frits van Rhee
    Blood 110:827-32. 2007
    ..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival...
  44. pmc Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:1587-94. 2007
    ..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM...
  45. pmc The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
    Yang Yang
    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Blood 110:2041-8. 2007
    ....
  46. ncbi request reprint Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    Jeffrey Haessler
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 13:7073-9. 2007
    ..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
  47. pmc IRF4 addiction in multiple myeloma
    Arthur L Shaffer
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 454:226-31. 2008
    ..Although IRF4 is not genetically altered in most myelomas, they are nonetheless addicted to an aberrant IRF4 regulatory network that fuses the gene expression programmes of normal plasma cells and activated B cells...
  48. ncbi request reprint Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38
    Jin Xie
    Myeloma Institute for Research and Therapy and Arkansas Cancer Research Center, Little Rock 72205, USA
    J Immunol 171:4792-800. 2003
    ..Thus, our study reveals that LPS has dual effects on DCs that are biologically important: activating existing DCs to initiate an immune response, and inhibiting the generation of new DCs to limit such a response...
  49. ncbi request reprint Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers
    Michael B Nichol
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90033, USA
    J Manag Care Pharm 13:360-71. 2007
    ..The Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions was intended as a tool to assist health care providers in evaluating and selecting drug products...
  50. ncbi request reprint Biocompatible nanofiber scaffolds on metal for controlled release and cell colonization
    Wenjun Dong
    Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, USA
    Nanomedicine 2:248-52. 2006
    ..The nanofibers can self-organize into macroporous (mostly 0.5-10 microm in diameter) scaffolds potentially useful for developing new bioscaffolds, photocatalysts, sensors, and drug delivery vehicles...

Research Grants5